Amgen To Achieve Carbon Neutrality By 2027 Read more about Amgen To Achieve Carbon Neutrality By 2027
Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference Read more about Amgen To Present At The 39th Annual J.P. Morgan Healthcare Conference
Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health Read more about Amgen Licenses AMG 634, An Investigational Treatment For Tuberculosis And Leprosy, To Medicines Development for Global Health
Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency Read more about Amgen Submits Sotorasib Marketing Authorization Application To The European Medicines Agency
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma Read more about Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral Read more about Amgen Awards Two Local Biotech Start-Ups With Golden Ticket To LabCentral
FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab) Read more about FDA Approves Amgen's RIABNI™ (rituximab-arrx), A Biosimilar To Rituxan® (rituximab)
Amgen To Transfer Listing Of Debt Securities To Nasdaq Read more about Amgen To Transfer Listing Of Debt Securities To Nasdaq
Amgen Announces 10% Increase In 2021 First Quarter Dividend Read more about Amgen Announces 10% Increase In 2021 First Quarter Dividend
Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation Read more about Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C Mutation
